These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31839821)

  • 1. Research progress on the relationship between lung cancer drug-resistance and microRNAs.
    Ma X; Liang AL; Liu YJ
    J Cancer; 2019; 10(27):6865-6875. PubMed ID: 31839821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    Zhao Y; Wang H; He C
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance.
    Dai C; Liu B; Li S; Hong Y; Si J; Xiong Y; Wu N; Ma Y
    Technol Cancer Res Treat; 2021; 20():15330338211056809. PubMed ID: 34825849
    [No Abstract]   [Full Text] [Related]  

  • 4. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
    Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
    Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
    Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Sin TK; Wang F; Meng F; Wong SC; Cho WC; Siu PM; Chan LW; Yung BY
    Int J Mol Sci; 2016 Feb; 17(2):237. PubMed ID: 26891293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.
    Hassanein SS; Ibrahim SA; Abdel-Mawgood AL
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines.
    Haque I; Kawsar HI; Motes H; Sharma M; Banerjee S; Banerjee SK; Godwin AK; Huang CH
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
    Ahmad A; Maitah MY; Ginnebaugh KR; Li Y; Bao B; Gadgeel SM; Sarkar FH
    J Hematol Oncol; 2013 Oct; 6(1):77. PubMed ID: 24199791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines.
    Meng F; Wang F; Wang L; Wong SC; Cho WC; Chan LW
    Front Genet; 2016; 7():197. PubMed ID: 27895663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.
    Leonetti A; Assaraf YG; Veltsista PD; El Hassouni B; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Jan; 42():1-11. PubMed ID: 30544036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma.
    Sun R; Hou Z; Zhang Y; Jiang B
    Oncol Lett; 2022 Nov; 24(5):408. PubMed ID: 36245822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Huang WC; Yadav VK; Cheng WH; Wang CH; Hsieh MS; Huang TY; Lin SF; Yeh CT; Kuo KT
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research Progress of the Role of EMT in EGFR-TKIs Resistance 
of Non-small Cell Lung Cancer].
    Yu L; Huang S; Lv W; He Z; Hu J
    Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):907-911. PubMed ID: 30591098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.